Targeting En2, Pax2, And/or Defb1 For Treatment Of Prostate Conditions

Abstract

The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression and/or PAX2 activity. The pharmaceutical composition may further comprise a third agent that enhances DEFB1 expression or activity.


Claims
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jun 11, 2013
  • Application: Dec 5, 2011
    US US 201113310940 A
  • Priority: Dec 5, 2011
    US US 201113310940 A
  • Priority: Feb 18, 2010
    US US 70829410 A
  • Priority: Sep 15, 2008
    US US 9019108 A
  • Priority: Oct 16, 2006
    US US 2006/0040215 W
  • Priority: Oct 14, 2005
    US US 72692105 P

Download Citation


Sign in to the Lens

Feedback